Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Novel immunotherapy combination can be highly effective for treating lung canceron January 26, 2021 at 9:11 pm
McMaster University researchers have established in lab settings that a novel combination of two forms of immunotherapy can be highly effective for treating lung cancer, which causes more deaths than ...
- Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Canceron January 26, 2021 at 9:20 am
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bic ...
- First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®on January 26, 2021 at 2:11 am
LEIDEN, The Netherlands, /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today ...
- Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industryon January 25, 2021 at 5:45 am
Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy ...
- Allergy Immunotherapy Market will reach a valuation of US$ 2,892.2 Mn by the end of 2030on January 25, 2021 at 5:23 am
Allergy Immunotherapy Market Players Promoting Novel Treatment Options to Reduce Reluctance – Future market Insights. Demand for allergy immunotherapy to ...
- What Is Immunotherapy? The Next Wave in Cancer Treatment, Explainedon January 24, 2021 at 7:46 am
For decades, the most effective treatments for cancer have involved surgery and rounds of chemotherapy or radiation. But some of those treatments can harm healthy cells, which is why advancements that ...
- Global Cellular Immunotherapy Market Report 2020-2030 - ResearchAndMarkets.comon January 23, 2021 at 12:14 am
COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering. Cellular Immunotherapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, ...
- Respiratory tract infections in children with allergic asthma on allergen immunotherapy during influenza season | Scientific Reportson January 22, 2021 at 6:00 am
To describle how respiratory tract infections (RTIs) that occurred in children with allergic asthma (AA) on allergen immunotherapy (AIT) during an influenza season. Data including clinical symptoms ...
- F-star Therapeutics: New Biologics Platform For Immunotherapyon January 21, 2021 at 8:00 am
Potential to close larger developmental deals from its platform and pipeline and the blockbuster potential of these drug candidates, make F-star a compelling long-term investment. F-star Therapeutics ...
- Study predicts good passive immunotherapy donors to combat COVID-19on January 19, 2021 at 10:09 am
A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.
via Bing News